CH Biotech R&D Co (TPE:6534) Stock Based Compensation: NT$0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6534 CH Biotech R&D Co Ltd TPE:6534
84 GF Score
Price NT$93.00
GF Value NT$100.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is CH Biotech R&D Co Stock Based Compensation?

CH Biotech R&D Co TPE:6534 +1.31% 84 Stock Based Compensation is NT$0 Mil as of Dec. 2025. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.82 (Fairly Valued). The stock has 1 warning sign investors should review.

CH Biotech R&D Co's Stock Based Compensation for the three months ended in Dec. 2025 was NT$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0 Mil.

CH Biotech R&D Co Stock Based Compensation Related Terms

CH Biotech R&D Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for CH Biotech R&D Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CH Biotech R&D Co Stock Based Compensation Chart

CH Biotech R&D Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.24 0.00 0.00

CH Biotech R&D Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TPE:6534
84GF Score
CH Biotech R&D Co Ltd TPE:6534
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CH Biotech R&D Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0 Mil.

What does a Stock Based Compensation of NT$0 Mil mean?
CH Biotech R&D Co (TPE:6534) has a Stock Based Compensation of NT$0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CH Biotech R&D Co and its competitors.
Is CH Biotech R&D Co's Stock Based Compensation too high?
CH Biotech R&D Co's current Stock Based Compensation is NT$0 Mil. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Stock Based Compensation compare to CTVA and CF?
CH Biotech R&D Co's Stock Based Compensation of NT$0 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for an Agriculture company?
A good Stock Based Compensation depends on the Agriculture industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for CH Biotech R&D Co and its competitors. CH Biotech R&D Co's current Stock Based Compensation is NT$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Fairly Valued. The stock's GF Value™ is NT$100.82, compared to a current price of NT$93.00 — trading 7.8% below its estimated fair value. The current Stock Based Compensation is NT$0 Mil. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Stock Based Compensation is NT$0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?

Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued. The current stock price of NT$93.00 is trading 7.8% below its estimated GF Value™ of NT$100.82. GuruFocus considers CH Biotech R&D Co to be Fairly Valued.

Key valuation signals for TPE:6534:

  • Stock Based Compensation: NT$0 Mil
  • GF Value™: NT$100.82 vs. price of NT$93.00 (7.8% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CH Biotech R&D Co Business Description

Address No. 89, Wenxian Road, Nantou County, Nantou City, TWN, 540001
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score

Get the complete analysis for TPE:6534

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$93.00
Price
NT$100.82
GF Value